A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

Autor: Elena Élez, Núria Mulet-Margalef, Miriam Sanso, Fiorella Ruiz-Pace, Francesco M. Mancuso, Raquel Comas, Javier Ros, Guillem Argilés, Giulia Martini, Enrique Sanz-Garcia, Iosune Baraibar, Francesc Salvà, Alba Noguerido, Jose Luis Cuadra-Urteaga, Roberta Fasani, Ariadna Garcia, Jose Jimenez, Susana Aguilar, Stefania Landolfi, Javier Hernández-Losa, Irene Braña, Paolo Nuciforo, Rodrigo Dienstmann, Josep Tabernero, Ramon Salazar, Ana Vivancos

Publikováno v: International Journal of Molecular Sciences; Volume 24; Issue 1; Pages: 118
Scientia

Biomarkers; Colorectal cancer; Immunotherapy Biomarcadors; Càncer colorectal; Immunoteràpia Biomarcadores; Cáncer colorrectal; Inmunoterapia The search for immunotherapy biomarkers in Microsatellite Instability High/Deficient Mismatch Repair syste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bacfe4702a115d21d52cef1988afcb
https://doi.org/10.3390/ijms24010118

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.

Autor: Élez E; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Mulet-Margalef N; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Sanso M; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Genomics for Precision Oncology Laboratory, Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), 07120 Palma de Mallorca, Spain., Ruiz-Pace F; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Mancuso FM; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Research and Development Department, Universal Diagnostics S.L., 41013 Sevilla, Spain., Comas R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Ros J; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Departament of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy., Argilés G; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Martini G; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Departament of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 81100 Naples, Italy., Sanz-Garcia E; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Baraibar I; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Salvà F; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Noguerido A; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Cuadra-Urteaga JL; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Medical Oncology, IOB-Hospital Quirón, 08023 Barcelona, Spain., Fasani R; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Garcia A; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Jimenez J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Aguilar S; Molecular Prescreening Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Landolfi S; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Hernández-Losa J; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Braña I; Medical Oncology Department, Research Unit for Molecular Therapy of Cancer, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Tabernero J; Colorectal Cancer Program, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Salazar R; Colorectal Cancer Unit, Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, Oncobell Program (IDIBELL), CIBERONC, L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Dec 21; Vol. 24 (1). Date of Electronic Publication: 2022 Dec 21.

Up-to-date role of aflibercept in the treatment of colorectal cancer.

Autor: Saoudi Gonzalez N; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Salvà F; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron Institute of Oncology, VHIO Barcelona, Spain., Ros J; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron Institute of Oncology, VHIO Barcelona, Spain., Baraibar I; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron Institute of Oncology, VHIO Barcelona, Spain., Marmolejo D; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Valdivia A; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cuadra-Urteaga JL; Medical Oncology Department, Oncological Institute of Barcelona, Barcelona, Spain., Mulet N; Medical Oncology Department, Vall d'Hebron Institute of Oncology, VHIO Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, lDIBELL, Bellvitge Biomedical Research Institute, L'Hospitalet De Llobregat, Spain., Tabernero J; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron Institute of Oncology, VHIO Barcelona, Spain., Élez E; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron Institute of Oncology, VHIO Barcelona, Spain.

Publikováno v: Expert opinion on biological therapy [Expert Opin Biol Ther] 2021 Oct; Vol. 21 (10), pp. 1315-1324. Date of Electronic Publication: 2021 Jun 13.

Outcome prognostic factors in inoperable malignant bowel obstruction.

Autor: Romeo M; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain. mromeo@iconcologia.net.; Universitat Autónoma de Barcelona, Barcelona, Spain. mromeo@iconcologia.net., de Los LLanos Gil M; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain., Cuadra Urteaga JL; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain., Vilà L; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain., Ahlal S; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain., Indacochea A; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain.; Center for Genomic Regulation (CRG), Vall d'Hebron Institut de Recerca, Barcelona, Spain., Pardo N; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain.; Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institut of Oncology, Barcelona, Spain., Radua J; FIDMAG Germanes Hospitalàries- CIBERSAM, Sant Boi de Llobregat, Spain.; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden., Font A; Medical Oncology Department, Institut Català d'Oncologia, Carretera del Canyet s/n, 08916, Badalona, Spain., Tuca A; Supportive Care in Cancer Unit, Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2016 Nov; Vol. 24 (11), pp. 4577-86. Date of Electronic Publication: 2016 Jun 10.

[Renal-cell carcinoma and multiple mieloma: synchronic association with posible immunologic pathogenesis].

Autor: Cuadra-Urteaga JL, Font Pous A, Pardo-Aranda N, Rocafiguera AO

Publikováno v: Medicina clinica [Med Clin (Barc)] 2012 Mar 03; Vol. 138 (5), pp. 224-5. Date of Electronic Publication: 2011 Jun 29.